Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Greasley

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Diabetes, Obesity & Metabolism|April 28, 2022
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMONDTaha Sen, Rosalie Scholtes, Peter J Greasley, et al.
Mucosal Immunology|April 13, 2025
A multi-omics microbiome signature is associated with the benefits of gastric bypass surgery and is differentiated from diet induced weight loss through 2 years of follow-upVancheswaran Gopalakrishnan, Chanchal Kumar, Ida Robertsen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 25, 2024
Proteinuria as an End Point in Clinical Trials of Focal Segmental GlomerulosclerosisLaura H Mariani, Howard Trachtman, Aliza Thompson, et al.
The Lancet. Diabetes & Endocrinology|June 20, 2020
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trialDavid Z I Cherney, Claire C J Dekkers, Sean J Barbour, et al.
JACC. Heart Failure|April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF TrialSu Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
Diabetes, Obesity & Metabolism|May 30, 2025
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trialJelle M Beernink, Niels Jongs, Charlotte M Mosterd, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 31, 2021
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label TrialNicola C Edwards, Anna M Price, Samir Mehta, et al.
Circulation|April 11, 2023
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HFSu Ern Yeoh, Kieran F Docherty, Ross T Campbell, et al.
European Journal of Heart Failure|September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HFCarly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
Clinical Pharmacokinetics|February 15, 2021
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney DiseaseAnnemarie B van der Aart-van der Beek, Jeroen V Koomen, Claire C J Dekkers, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Diabetes, Obesity & Metabolism|April 28, 2022
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMONDTaha Sen, Rosalie Scholtes, Peter J Greasley, et al.
Mucosal Immunology|April 13, 2025
A multi-omics microbiome signature is associated with the benefits of gastric bypass surgery and is differentiated from diet induced weight loss through 2 years of follow-upVancheswaran Gopalakrishnan, Chanchal Kumar, Ida Robertsen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 25, 2024
Proteinuria as an End Point in Clinical Trials of Focal Segmental GlomerulosclerosisLaura H Mariani, Howard Trachtman, Aliza Thompson, et al.
The Lancet. Diabetes & Endocrinology|June 20, 2020
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trialDavid Z I Cherney, Claire C J Dekkers, Sean J Barbour, et al.
JACC. Heart Failure|April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF TrialSu Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
Diabetes, Obesity & Metabolism|May 30, 2025
Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trialJelle M Beernink, Niels Jongs, Charlotte M Mosterd, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 31, 2021
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label TrialNicola C Edwards, Anna M Price, Samir Mehta, et al.
Circulation|April 11, 2023
Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HFSu Ern Yeoh, Kieran F Docherty, Ross T Campbell, et al.
European Journal of Heart Failure|September 2, 2022
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HFCarly Adamson, Lorna M Cowan, Rudolf A de Boer, et al.
Clinical Pharmacokinetics|February 15, 2021
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney DiseaseAnnemarie B van der Aart-van der Beek, Jeroen V Koomen, Claire C J Dekkers, et al.
Pageof 9